[go: up one dir, main page]

AR044069A1 - Un metodo de diuresis mejorada en individuos con funcion renal deteriorada - Google Patents

Un metodo de diuresis mejorada en individuos con funcion renal deteriorada

Info

Publication number
AR044069A1
AR044069A1 ARP040101381A ARP040101381A AR044069A1 AR 044069 A1 AR044069 A1 AR 044069A1 AR P040101381 A ARP040101381 A AR P040101381A AR P040101381 A ARP040101381 A AR P040101381A AR 044069 A1 AR044069 A1 AR 044069A1
Authority
AR
Argentina
Prior art keywords
diuretic
individuals
renal function
metabolite
prodrug
Prior art date
Application number
ARP040101381A
Other languages
English (en)
Inventor
Scott Thomson
Kenneth J Widder
Lauren Otsuki
Roland Blantz
Howard C Dittrich
Original Assignee
Nova Cardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Cardia Inc filed Critical Nova Cardia Inc
Publication of AR044069A1 publication Critical patent/AR044069A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica que comprende una cantidad terapéuticamente efectiva de KW-3902, o una sal, éster, amida, metabolito o prodroga del mismo, y un diurético que no modifique la adenosina. Métodos para inducir un efecto diurético en un animal que comprenden el paso de administrar una cantidad terapéuticamente efectiva de KW-3902, o una sal, éster, amida, metabolito o prodroga del mismo, en combinación con una segunda composición farmacéutica capaz de inducir un efecto diurético. El KW- 3902 es un antagonista del receptor de adenosina A1 derivado de Xantina (AA1RA). Su nombre químico es 8-(3-noradamantil)-1,3-dipropilxantina, conocida también como 3,7-dihidro-1,3-dipropil-8-(3-triciclo[3.3.1.03,7]nonil)-1H-purina-2,6- diona. Reivindicación 5: La composición de acuerdo con la reivindicación 1, donde el diurético se selecciona dentro del grupo consistente en hidroclorotiazidas, furosemida, torsemida, bumetanida, ácido etacrínico, piretanida, norsemida, espironolactona, triamterene y amiloridetiazidas.
ARP040101381A 2003-04-25 2004-04-23 Un metodo de diuresis mejorada en individuos con funcion renal deteriorada AR044069A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46600703P 2003-04-25 2003-04-25

Publications (1)

Publication Number Publication Date
AR044069A1 true AR044069A1 (es) 2005-08-24

Family

ID=33418325

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101381A AR044069A1 (es) 2003-04-25 2004-04-23 Un metodo de diuresis mejorada en individuos con funcion renal deteriorada

Country Status (16)

Country Link
US (3) US7579331B2 (es)
EP (1) EP1620107A1 (es)
JP (1) JP2006524699A (es)
KR (1) KR20060004959A (es)
CN (1) CN1859913A (es)
AR (1) AR044069A1 (es)
AU (1) AU2004233852A1 (es)
BR (1) BRPI0409699A (es)
CA (1) CA2522971A1 (es)
MX (1) MXPA05011371A (es)
NO (1) NO20055536L (es)
NZ (1) NZ543109A (es)
RU (1) RU2367442C2 (es)
TW (1) TW200500070A (es)
WO (1) WO2004096228A1 (es)
ZA (1) ZA200509311B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
AR044069A1 (es) 2003-04-25 2005-08-24 Nova Cardia Inc Un metodo de diuresis mejorada en individuos con funcion renal deteriorada
CA2536975A1 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
CA2568436A1 (en) * 2004-04-16 2005-11-10 Novacardia, Inc. Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
US7396829B2 (en) * 2005-02-24 2008-07-08 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
CN101166515A (zh) * 2005-04-22 2008-04-23 美国诺华卡迪亚公司 用于非水溶性药物成分静脉注射的乳剂的生产
AU2006325984A1 (en) * 2005-12-14 2007-06-21 Kyowa Hakko Kirin Co., Ltd. Easily absorbed oral preparation containing xanthine derivative
CN101420958A (zh) * 2006-04-06 2009-04-29 挪瓦卡尔迪阿公司 共投与腺苷a1受体拮抗剂和抗惊厥药
CN101466435A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 Kw-3902在充血性心脏衰竭和急性体液超负荷患者中实现利尿作用的用途
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416810C (sv) 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
FR2531085A1 (fr) 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4769377A (en) * 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
SE9000207L (sv) 1990-01-22 1991-07-23 Nobel Chemicals Ab Laekemedel samt anvaendningen av detsamma
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
AU2297192A (en) 1991-06-28 1993-01-25 Sepracor, Inc. Optically pure s(-) nadolol for treatment of cardiovascular disorders
CA2093403C (en) 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
TW252044B (es) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
DE4238367A1 (de) * 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
CN1049117C (zh) 1994-09-16 2000-02-09 赵明玉 预防和治疗偏头痛的偏头痛片
ATE240734T1 (de) * 1995-07-26 2003-06-15 Kyowa Hakko Kogyo Kk Zubereitung von xanthinderivaten als feste dispersion
AU3784597A (en) * 1996-08-07 1998-02-25 Kyowa Hakko Kogyo Co. Ltd. Fat emulsion containing xanthine derivative
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO1999055339A1 (en) * 1998-04-24 1999-11-04 Biogen, Inc. Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function
US20020115687A1 (en) * 1998-04-24 2002-08-22 Evan Beckman Method and composition for restoring diuretic and renal function
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
TR200201260T2 (tr) * 1999-11-12 2002-09-23 Biogen, Inc. Adenosin reseptör antagonistleri olarak polisikloalkilpurinler.
GEP20043267B (en) * 1999-11-12 2004-06-25 Biogen Inc Us Adenosine Receptor Antagonists, Methods of Making and Using the Same
US20050038017A1 (en) * 1999-12-22 2005-02-17 Wolff Andrew A. Method and composition for restoring diuretic and renal function
AU2002219977B2 (en) * 2000-12-01 2008-01-24 Biogen Idec Ma Inc. Condensed purine derivatives as A1 adenosine receptor antagonists
CN1461218A (zh) 2000-12-18 2003-12-10 诺瓦提斯公司 阿洛地平和贝那普利的治疗组合
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US20040229901A1 (en) 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
AR044069A1 (es) 2003-04-25 2005-08-24 Nova Cardia Inc Un metodo de diuresis mejorada en individuos con funcion renal deteriorada
WO2005000294A1 (en) * 2003-06-06 2005-01-06 Pharmacia Corporation Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
CA2568436A1 (en) * 2004-04-16 2005-11-10 Novacardia, Inc. Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
US7517888B2 (en) * 2004-04-28 2009-04-14 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
CN101420958A (zh) * 2006-04-06 2009-04-29 挪瓦卡尔迪阿公司 共投与腺苷a1受体拮抗剂和抗惊厥药
CN101466435A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 Kw-3902在充血性心脏衰竭和急性体液超负荷患者中实现利尿作用的用途
EP2035009A1 (en) 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
JP2010501557A (ja) * 2006-08-22 2010-01-21 ノヴァカーディア，インク． 血液脳関門を通過しないｋｗ−３９０２コンジュゲート

Also Published As

Publication number Publication date
JP2006524699A (ja) 2006-11-02
RU2005131938A (ru) 2006-06-27
TW200500070A (en) 2005-01-01
WO2004096228A1 (en) 2004-11-11
AU2004233852A1 (en) 2004-11-11
CA2522971A1 (en) 2004-11-11
NZ543109A (en) 2008-06-30
BRPI0409699A (pt) 2006-04-18
US20060030572A1 (en) 2006-02-09
NO20055536L (no) 2005-12-29
MXPA05011371A (es) 2005-12-01
US20050004145A1 (en) 2005-01-06
US20060035911A1 (en) 2006-02-16
KR20060004959A (ko) 2006-01-16
ZA200509311B (en) 2006-10-25
NO20055536D0 (no) 2005-11-23
RU2367442C2 (ru) 2009-09-20
CN1859913A (zh) 2006-11-08
US7579331B2 (en) 2009-08-25
EP1620107A1 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
AR044069A1 (es) Un metodo de diuresis mejorada en individuos con funcion renal deteriorada
Jacobson et al. Adenosine receptor ligands: differences with acute versus chronic treatment
De Sarro et al. Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice
Zocchi et al. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.
Baraldi et al. Synthesis and Biological Activity of a New Series of N 6-Arylcarbamoyl, 2-(Ar) alkynyl-N 6-arylcarbamoyl, and N 6-Carboxamido Derivatives of Adenosine-5 ‘-N-ethyluronamide as A1 and A3 Adenosine Receptor Agonists
Jacobson et al. A role for central A3-adenosine receptors: Mediation of behavioral depressant effects
Rogawski AMPA receptors as a molecular target in epilepsy therapy
Baraldi et al. Pyrazolo [4, 3-e]-1, 2, 4-triazolo [1, 5-c] pyrimidine derivatives as highly potent and selective human A3 adenosine receptor antagonists
Abebe et al. Adenosine receptor-mediated relaxation of porcine coronary artery in presence and absence of endothelium
Garção et al. Functional interaction between pre‐synaptic α6β2‐containing nicotinic and adenosine A2A receptors in the control of dopamine release in the rat striatum
Clinckers et al. Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10, 11-dihydro-10-hydroxycarbamazepine
Feoktistov et al. Inhibition of human mast cell activation with the novel selective adenosine A2B receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)
Prentice et al. Activation of multiple sites by adenosine analogues in the rat isolated aorta
CH669730A5 (es)
DE69842121D1 (de) Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
WO1998030900A2 (en) Screening method for compounds active in treating myopia and hypermetropia
Kotagale et al. Chronic agmatine treatment prevents behavioral manifestations of nicotine withdrawal in mice
Simon DMARDs in the treatment of rheumatoid arthritis: current agents and future developments
Landsberg et al. Effects of clomipramine on cats presented for urine marking
Zarrindast et al. Effects of adenosine receptor agonists and antagonists on acquisition of passive avoidance learning
Nikodijević et al. Characterization of the locomotor depression produced by an A2‐selective adenosine agonist
Clark et al. Effect of acute ethanol on release of endogenous adenosine from rat cerebellar synaptosomes
Doyle et al. Time and sex-dependent effects of an adenosine A2A/A1 receptor antagonist on motivation to self-administer cocaine in rats
Abad et al. Adaptive plasticity in the hippocampus of young mice intermittently exposed to MDMA could be the origin of memory deficits
Mirabet et al. Calcium mobilization in Jurkat cells via A2b adenosine receptors

Legal Events

Date Code Title Description
FB Suspension of granting procedure